SCOLR Pharma, Inc. Names Carl Johnson as Chairman

SCOLR Pharma, Inc. (DDD) today announced that Carl Johnson has been appointed as the Chairman of its Board of Directors. Johnson succeeds Michael Taglich, who will remain a member of the Board. Johnson previously served as President and Chief Executive Officer of Matrixx Initiatives, Inc. Under Johnson's leadership, Matrixx successfully developed and launched the Zicam® product line. Johnson also has served as Vice President, Commercial Development, for Perrigo Company and before that was with Johnson & Johnson in both the consumer and professional healthcare products divisions. Johnson was elected a director of SCOLR at its annual meeting in June.